Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Net Income towards Common Stockholders (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Net Income towards Common Stockholders for 12 consecutive years, with $295951.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income towards Common Stockholders rose 124.71% year-over-year to $295951.0, compared with a TTM value of -$6.0 million through Sep 2025, down 8.76%, and an annual FY2024 reading of -$5.1 million, down 13.94% over the prior year.
  • Net Income towards Common Stockholders was $295951.0 for Q3 2025 at Sunshine Biopharma, up from -$3.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $667116.0 in Q4 2021 and bottomed at -$23.5 million in Q4 2022.
  • Average Net Income towards Common Stockholders over 5 years is -$2.8 million, with a median of -$1.3 million recorded in 2024.
  • The sharpest move saw Net Income towards Common Stockholders crashed 3624.47% in 2022, then surged 124.71% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at $667116.0 in 2021, then plummeted by 3624.47% to -$23.5 million in 2022, then surged by 94.68% to -$1.3 million in 2023, then tumbled by 72.65% to -$2.2 million in 2024, then soared by 113.71% to $295951.0 in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for SBFM at $295951.0 in Q3 2025, -$3.0 million in Q2 2025, and -$1.2 million in Q1 2025.